U.S. Consumer Durables Stock News

Earlier this week, Raymond James reaffirmed its Strong Buy rating on Old Second Bancorp after the bank presented at the Raymond James Small Cap Bank Summit, highlighting confidence in the Evergreen Bank deal, its powersports lending niche, and steady loan growth prospects. The firm also underlined Old Second’s interest in acquiring another small bank in the Chicago metropolitan area, signaling continued expansion ambitions that could reshape its regional footprint and business mix over...

If you have been wondering whether Brinker International is still a bargain or if most of the upside is already priced in, you are not alone. This article is going to dig into that value question head on. After a powerful multi year run that has pushed the stock up 332.9% over 3 years and 165.5% over 5 years, the shares have cooled slightly with a 6.4% drop over the last week following a strong 35.2% gain in the past month. Much of the recent move has been driven by renewed optimism around...

In November 2025, Lotus Technology Inc. reported third-quarter 2025 results showing revenue of US$137.43 million and a net loss of US$65.42 million, alongside 4,612 vehicle deliveries over the first nine months of the year amid tariffs, destocking, and phased upgraded model launches. While revenue fell sharply year on year, the smaller loss per share suggests cost controls are starting to take effect even as delivery volumes remain pressured by external and operational headwinds. With...

If you are wondering whether Dynavax Technologies is quietly turning into a value opportunity or just another biotech rollercoaster, you are in the right place. The stock has slipped about 4% over the last week but is still up roughly 9.2% over the past month, even though it remains down around 15.0% year to date and 14.5% over the last year, after a strong 140.0% gain over five years. Recent attention has centered on Dynavax's expanding role in vaccine adjuvants and partnerships that aim to...

If you are wondering whether Nutanix at around $47 a share is a bargain in disguise or a value trap waiting to happen, this breakdown is for you. The stock has slid about 33.3% over the last month and is down 22.6% year to date, yet it is still sitting on gains of roughly 57.4% over 3 years and 59.6% over 5 years. That kind of whiplash in returns has coincided with shifting sentiment around high growth software names, as investors rotate between riskier cloud stories and more predictable...

CureVac (NasdaqGM:CVAC) has just been dropped from the NASDAQ Biotechnology Index, a mechanical change that can still matter for investors as index tracking funds trim positions and liquidity dynamics start to shift. See our latest analysis for CureVac. That index removal lands after a busy stretch for CureVac, including new board appointments and mixed earnings. It also comes at a time when the share price has climbed sharply year to date, although longer term total shareholder returns still...

Absci (ABSI) just crossed an important milestone by dosing the first healthy volunteers in its Phase 1/2a HeadLINE trial for ABS-201, an AI designed antibody targeting androgenetic alopecia and, later, endometriosis. See our latest analysis for Absci. The ABS-201 milestone lands after a volatile stretch, with the share price up 8.6 percent over one day and 6.5 percent over seven days, yet still showing a negative 30 day share price return while the 1 year total shareholder return remains...

If you are wondering whether Science Applications International is quietly turning into a value opportunity after a rough stretch in the market, you are not alone. This is exactly what we are going to unpack. The stock now trades around $87.53, up 2.1% over the last week but still down 4.2% over 30 days and 22.0% year to date, reflecting a market that has cooled on the name after a longer 1 year slide of 28.4%. In recent months, investor attention has been shaped more by shifting sentiment...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

As the Dow Jones and S&P 500 approach record highs, buoyed by expectations of a potential Federal Reserve rate cut, the U.S. tech sector remains a focal point for investors navigating an evolving economic landscape marked by mixed employment data and fluctuating Treasury yields. In such a dynamic environment, identifying high-growth tech stocks involves assessing factors like innovation potential, market positioning, and adaptability to macroeconomic shifts that can influence performance in...

As the Dow Jones and S&P 500 approach record highs, investors are closely watching market movements amidst expectations of a potential interest rate cut by the Federal Reserve. In this environment, identifying stocks that may be trading below their intrinsic value can offer opportunities for those seeking to capitalize on market inefficiencies.

As the Dow Jones and S&P 500 approach record highs, investors are keeping a close eye on market movements and potential interest rate cuts by the Federal Reserve. Investing in penny stocks—though a somewhat outdated term—remains relevant as these stocks often represent smaller or newer companies that can offer unique growth opportunities. By focusing on those with strong financials, investors may uncover hidden gems poised for long-term success amidst current market conditions.

You may think that with a price-to-sales (or "P/S") ratio of 9.6x Clearwater Analytics Holdings, Inc. ( NYSE:CWAN ) is...

In December 2025, Black Stone Minerals, L.P. announced it had entered into a multi-year development agreement with an affiliate of Caturus Energy, covering 220,000 gross acres in the Shelby Trough and Haynesville Expansion to support growing Gulf Coast natural gas demand. The deal outlines a structured ramp-up from pilot wells in the first two years to about 12 gross wells annually by year six, potentially unlocking more value from Black Stone’s roughly 40,000 undeveloped net acres in the...

Axsome Therapeutics (AXSM) just followed up a 63% year over year revenue jump with plans to showcase its growth story at the Piper Sandler Healthcare Conference, putting Auvelity, Sunosi and new migraine drug Symbravo firmly in the spotlight. See our latest analysis for Axsome Therapeutics. That growth narrative is increasingly reflected in the market, with Axsome’s share price at $147.81 and a roughly 69% year to date share price return pointing to building momentum. The three year total...

Camtek (CAMT) is back on many radar screens after Morgan Stanley initiated coverage, alongside a wave of rating upgrades from other brokerages, a cluster of fresh opinions that often nudges sentiment and trading activity. See our latest analysis for Camtek. That growing analyst enthusiasm has arrived on the back of strong momentum, with the share price at $116.93 after a 5.44% 1 day share price return and a standout 48.48% 90 day share price return. The 5 year total shareholder return of...

In the past quarter, Yext reported annual recurring revenue growth of 9.1% year-on-year alongside a worsening operating margin, highlighting rising cost pressures and competitive headwinds. A negative customer acquisition cost payback period underscored that recent sales and marketing spending has yet to convert into sustainable, profitable growth. We’ll now explore how Yext’s modest recurring revenue growth and weak customer acquisition efficiency may reshape its broader investment...

In early December 2025, Wolfspeed, Inc. reported receiving a US$698.6 million cash tax refund from the IRS under the Advanced Manufacturing Investment Credit, boosting liquidity as it ramps its 200mm silicon carbide manufacturing footprint and earmarks funds to retire about US$175 million of debt. This refund is particularly important because Wolfspeed only recently emerged from Chapter 11 bankruptcy and continues to contend with ongoing cash burn and financial pressure while expanding into...

IQVIA Holdings (IQV) just posted quarterly results that cleared the bar on both revenue and earnings, with organic growth and helpful currency shifts pushing sales up 5.2% and adjusted EPS up 6% year over year. See our latest analysis for IQVIA Holdings. Those solid quarterly beats come on top of a strong run, with IQVIA’s share price up a robust 23.45% over the past three months and its 11.85% one year total shareholder return pointing to gradually improving sentiment rather than euphoric...

PriceSmart's (NASDAQ:PSMT) stock is up by a considerable 15% over the past three months. Given that the market rewards...

GitLab (GTLB) just posted its Q3 2026 numbers, landing revenue at about $244 million with basic EPS of roughly -$0.05 as the company continues to prioritize growth over bottom line profits. The company has seen revenue step up from around $183 million in Q2 2025 to $196 million in Q3 2025, then $211 million in Q4 2025 and $214 million, $236 million and now $244 million across the first three quarters of 2026. At the same time, EPS swung from a positive $0.18 in Q3 2025 to modest losses...

If you are wondering whether Cinemark Holdings is a beaten down bargain or a value trap, you are in the right place to unpack what the current share price is really telling us. The stock has slid sharply in the short term, down 16.8% over the last week, 14.4% over the past month, and 26.1% year to date, even though it is still up 92.7% over three years and 52.9% over five years. These swings have come as investors reassess the long term prospects for movie theaters amid shifting box office...

If you have been wondering whether XP is still a bargain after its recent run, this breakdown will help you decide if the current price makes sense or if there is more upside on the table. The stock is up 0.7% over the last week, 6.2% over the past month, and an eye catching 62.8% year to date, though the 5 year return of -42.4% is a reminder that sentiment around XP can swing sharply. Recent headlines have focused on XP’s continued expansion of its digital investment platform in Brazil and...

If you have been wondering whether Rithm Capital is still good value after its recent run, you are not alone. This stock is starting to pop up on a lot more radar screens. Over the last year Rithm is up about 12.0%, building on a strong multi year climb of roughly 71.6% over three years and 94.7% over five years, even though the past week has seen a mild pullback of around 0.9% after a 3.2% rise over the last month. That climb has come alongside a steady repositioning of the business toward...